Modulators of retinol-retinol binding protein...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S613000, C514S699000, C514S741000, C514S912000

Reexamination Certificate

active

07432307

ABSTRACT:
Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.

REFERENCES:
patent: 4190594 (1980-02-01), Gander et al.
patent: 4323581 (1982-04-01), Gander
patent: 4665098 (1987-05-01), Gibbs et al.
patent: 4743400 (1988-05-01), Maryanoff
patent: 4874795 (1989-10-01), Yessair
patent: 5023252 (1991-06-01), Hseih
patent: 5314909 (1994-05-01), Dollerup
patent: 5399757 (1995-03-01), Maryanoff
patent: 5427571 (1995-06-01), Sells
patent: 5596011 (1997-01-01), Repine et al.
patent: 5776915 (1998-07-01), Peterson et al.
patent: 5814612 (1998-09-01), Buck et al.
patent: 6034211 (2000-03-01), Kelly
patent: 6051692 (2000-04-01), Bandman et al.
patent: 6075032 (2000-06-01), Campochiaro et al.
patent: 6093706 (2000-07-01), Zeligs
patent: 6128870 (2000-10-01), Kohler
patent: 6458029 (2002-10-01), Morris
patent: 6482802 (2002-11-01), Hu et al.
patent: 6503242 (2003-01-01), Ellsberry
patent: 6506917 (2003-01-01), Evans et al.
patent: 6599891 (2003-07-01), North et al.
patent: 6696606 (2004-02-01), Curley, Jr. et al.
patent: 6875767 (2005-04-01), Bilodeau et al.
patent: 2002/0031539 (2002-03-01), Plutzky et al.
patent: 2002/0128291 (2002-09-01), Campochiaro et al.
patent: 2002/0143062 (2002-10-01), Lopez-Berestein et al.
patent: 2002/0183394 (2002-12-01), Gupta et al.
patent: 2002/0193065 (2002-12-01), Morris et al.
patent: 2003/0004418 (2003-01-01), Marmorstein
patent: 2003/0022831 (2003-01-01), Rothbard et al.
patent: 2003/0032078 (2003-02-01), Travis
patent: 2004/0092435 (2004-05-01), Peyman
patent: 2004/0102650 (2004-05-01), Curley, Jr. et al.
patent: 2004/0177387 (2004-09-01), Jayakrishna
patent: 2006/0069078 (2006-03-01), Rando
patent: 2006/0135469 (2006-06-01), Widder et al.
patent: 2006/0167088 (2006-07-01), Widder et al.
patent: 2007/0015827 (2007-01-01), Widder et al.
patent: 3610531 (1986-10-01), None
patent: 10038641 (2002-02-01), None
patent: 0258865 (1990-11-01), None
patent: 11-503998 (1999-06-01), None
patent: WO-99-08682 (1999-02-01), None
patent: WO00/21528 (2000-04-01), None
patent: WO-2001-19770 (2001-03-01), None
patent: WO 02/067917 (2002-09-01), None
patent: WO03/082081 (2003-10-01), None
patent: WO-01-38344 (2004-05-01), None
patent: WO-01-38344 (2004-05-01), None
patent: WO-2004-050101 (2004-06-01), None
patent: WO-2004-050101 (2004-06-01), None
patent: WO 2004/069203 (2004-08-01), None
patent: WO-2004-084883 (2004-10-01), None
patent: WO-2004-098506 (2004-11-01), None
patent: WO-2004-098506 (2004-11-01), None
patent: WO-2004-059564 (2005-06-01), None
patent: WO-2005-077176 (2005-08-01), None
patent: WO-2005-079774 (2005-09-01), None
patent: WO-2005-087210 (2005-09-01), None
patent: WO-2007-019503 (2005-09-01), None
patent: WO-2007-019503 (2005-09-01), None
patent: WO-2006-033734 (2006-03-01), None
patent: WO-2006-033734 (2006-03-01), None
patent: WO-2006-052860 (2006-05-01), None
patent: WO-2006-052860 (2006-05-01), None
Noy et al. Interactions of retinol with binding proteins: studies with retinol-binding protein and with transthyretin. Biochemistry 1992, vol. 31, pp. 11118-11124.
U.S. Appl. No. 60/578,324, filed Jun. 9, 2004, Robert R. Rando.
U.S. Appl. No. 60/567,604, filed Mar. 3, 2004, Robert R. Rando.
U.S. Appl. No. 60/545,456, filed Feb. 17, 2004, Robert R. Rando.
R. Allikmets et al., Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration, Science, vol. 277 (Sep. 19, 1997).
R. Allikmets, “Simple and Complex ABCR: Genetic Predisposition to Retinal Disease,” Am. J. Hum. Genet. 67:793-799, Columbia University, NY (2000).
W. Baehr et al., “The retinoid cycle and retina disease,” Vision Research 43 (2003) 2957-2958.
L. Baglietto et al., “Ocular Effects of Fenretinade, a Vitamin A Analog, in a Chemoprevention Trial of Bladder Cancer,” Cancer Detection and Prevention 24(4):369-375 (2000).
M. L. Batten et al., “Lecithin-retinol Acyltransferase Is Essential for Accumulation of All-trans-Retinyl Esters in the Eye and in the Liver,” J. of Biol. Chem., vol. 279, No. 11, Mar. 12, 2004, pp. 10422-10432.
D.R. Bergsma et al., “Vitamin A Receptors in Normal and Dystrophic Human Retina,” Nature, vol. 265 (Jan. 6, 1977).
J.W. Berkow, M.D., “Subretinal Neovascularization in Senile Macular Degeneration,” Am. J. of Ophthamology 97:143-147 (1984).
P.S. Bernstein, R.R. Rando, “In Vivo Isomerization of All-Trans-to 11-CIS-Retinoids in the Eye Occurs at the Alcohol Oxidation State,” Biochemistry Oct. 21, 1986; 25(21):6473-6478.
D. Besch et al., “Inherited multifocal RPE-diseases: mechanisms for local dysfunction in global retinoid cycle gene defects,” Vision Res. Dec. 2003;43(28):3095-108.
A. Bindewald, M.D. et al., “Visualization of Retinal Pigment Epithelial Cells in Vivo Using Digital High-Resolution Confocal Scanning Laser Ophthalmology,” Am J. of Ophthalmology, Mar. 2004, pp. 556-558.
D. Bok, “New insights and new approaches toward the study of age-related macular degeneration,” PNAS, Nov. 12, 2002, vol. 99 No. 23, 14619-14621.
R.C. Caruso, M.D. et al., “Effects of Fenretindate (4-HPR) on Dark Adaption,” Arch. Ophthalmology, vol. 116 (Jun. 1998) pp. 739,760-763.
S. Chen et al., “Differentiation of Human Retinal Pigment Epithelial Cells into Neuronal Phenotype by N-(4-Hydroxyphenyl) Retinamide,” J. Neurochem. (2003) 84, 972-981.
A.V. Cideciyan et al., “Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence,” Hum. Mol. Genet. 13(5) (2004) pp. 525-534.
J.W. Crabb et al., “Drusen Proteome Analysis: An Approach tothe Etiology of Age-Related Macular Degeneration,” PNAS (Nov. 12, 2002) vol. 99 No. 23, pp. 14682-14687.
F.P.M. Cremers et al., “Autosomal Recessive Retinitis Pigmentosa and Cone-Rod Dystophy Caused by Splice Site Mutations in the Stargardt's Disease Gene ABCR,” Human Molecular Genetics (1998) vol. 7 No. 3, pp. 355-362.
R.K. Crouch and P. Goletz, “Fenretinide Does Not Block Visual Pigment Formation in the Rat,” J. of Ocular Pharmacology, vol. 4 No. 3, 1988, pp. 253-256.
A. Decensi et al., “Effect of the Synthetic Retinoid Fenretinide on Dark Adaption and the Occular Surface,” J. of the National Cancer Inst., vol. 86, No. 2 (Jan. 19, 1994) pp. 105-110.
A. Decensi et al., “Long-Term Effects of Fenretinide on Retinal Function,” Eur. F. Cancer, vol. 33 No. 1, pp. 80-84 (1997).
F.C. Delori, “Autofluorescence method to measure macular pigment optical densities fluorometry and autofluorescence imaging,” Archives of Biochem. And Biophysics 430 (2004) pp. 156-162.
S.E. Dew et al., “Effects of Pharmacological Retinoids on Several Vitamin A-Metabolizing Enzymes,” Cancer Res. 53, 2965-2969 (Jul. 1, 1993).
F.L. Ferris, III, M.D. and R.D. Sperduto, M.D., “Standardized Illumination for Visual Activity Testing in Clinical Research,” Am. J. of Ophthalmology 94:97098 (1982).
S.C. Finneman et al., “The Lipfuscin Component A2E Selectively Inhibits Phagolysosomal Degradation of Photoreceptor Phospholipid by the Retinal Pigment Epithelium,” PNAS Mar. 19, 2002, vol. 99, No. 6, pp. 3842-3847.
F.Formelli et al., “Five-Year Administration of Fenretinide: Pharmacokinetics and Effects on Plasma Retinol Concentrations,” J. of Clinical Oncology, vol. 11, No. 10 (Oct. 1993) pp. 2036-2042.
F. Formelli et al., “Plasma Retinol Level Reduction by Synthetic Retinoid Fenretinide: A One Year Follow-Up Study of Breast Cancer Patients,” Cancer Res. 49, 6149-6152, Nov. 1, 1999.
F.T. Fraunfelder, M.D. et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Modulators of retinol-retinol binding protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of retinol-retinol binding protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of retinol-retinol binding protein... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4011571

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.